Can You Take Wegovy and Orlistat Together?

Step 1: understand what each medicine is doing on its own

Before asking whether orlistat and Wegovy can be taken together, it helps to be clear on what each one does independently. Wegovy is a once-weekly injection of semaglutide, a GLP-1 receptor agonist licensed in the UK for weight management. It works primarily by acting on appetite-regulating pathways in the brain and by slowing the rate at which the stomach empties, so you feel full sooner and stay full longer. The full Wegovy overview covers the mechanism in detail.

Orlistat is a lipase inhibitor. It works locally in the gut rather than centrally, it blocks the enzyme that breaks down dietary fat, meaning roughly a third of the fat you eat passes through undigested. It has no effect on appetite signalling and no GLP-1 activity whatsoever. The question of whether orlistat is a semaglutide comes up often, and the answer is a clear no: they are completely different drug classes.

Because the mechanisms are so different, it might seem logical that the two would complement each other. In practice, though, different mechanisms also mean different profiles of gut disruption, and layering those disruptions is where the problem starts.

Step 2: map what combining them actually means for your gut

The most immediate concern with combining semaglutide and orlistat is the additive burden on the gastrointestinal tract. The NHS medicines page for semaglutide lists nausea, vomiting, diarrhoea and stomach pain as common side effects, especially in the early weeks of treatment or after a dose increase. Orlistat's most predictable side effects are oily stools, urgent loose bowel movements and abdominal cramping, the direct result of undigested fat passing through the colon.

Taken alone, each medicine asks something of the gut. Taken together, the picture compounds quickly. Semaglutide slows gastric emptying; orlistat increases the volume and altered consistency of what eventually moves through. There is no clinical trial data on how the two interact, which is itself a problem, neither prescribers nor patients can be sure what to expect.

There is also a subtler concern. Orlistat reduces the absorption of fat-soluble vitamins (A, D, E and K). Semaglutide-induced nausea can already make eating a well-balanced diet harder in the early months of treatment. Running both simultaneously could deepen any nutritional gaps.

Step 3: consider whether a switch rather than an overlap is the right move

The clinical question most people are actually asking when they search for orlistat and Wegovy together is this: I've been on one of these and I want to try the other, do I stop first, or can I bridge? The answer is that switching requires prescriber input, not self-management. There is no overlap period described in either medicine's licensed guidance.

If you are currently taking orlistat and considering semaglutide, your prescriber will typically want to confirm orlistat has been stopped before starting Wegovy. The comparison of orlistat and Wegovy explains the differences in how they are used, including why semaglutide tends to be considered the more clinically substantial step for people with obesity. Wegovy is supported by NICE guidance (TA875) and trial data showing approximately 15% average body-weight reduction over 68 weeks, figures that have no equivalent in the orlistat evidence base.

It is also worth doing a quick check of any other medicines you take. Some medicines, including some that affect gut motility, can interact with either drug. A one-minute scan of your current prescription list before your consultation gives your prescriber the full picture from the start. Context on the wider semaglutide treatment pathway is also covered in the semaglutide treatment guide.

Step 4: what the licensed route for weight management actually looks like

For weight management in adults, the UK has two GLP-1 receptor agonist injections licensed, Wegovy (semaglutide) and Mounjaro (tirzepatide). Orlistat occupies a different part of the pathway: it is available at lower strength over the counter and at prescription strength via a GP, and it predates the GLP-1 class by decades. The two approaches are not designed to run in parallel.

People sometimes arrive at this question after exploring options that go beyond the licensed path, including combining products from different clinical categories. It is worth reading about taking Saxenda and Wegovy together as a comparable situation, same principle applies: two weight-loss medicines at once is not supported by evidence or licensing.

Cost is another factor in why people explore combinations. If the cost of Wegovy is a consideration, a clearer picture of what is actually included in private treatment pricing is on the Wegovy price comparison page. The NHS orlistat page is a useful reference for understanding what that medicine does and does not do on its own. If you want to discuss which licensed weight-loss treatment is appropriate for your situation, starting a free consultation puts the question in front of a named prescriber the same day.